Liquidia (LQDA) Projected to Post Quarterly Earnings on Thursday

Liquidia (NASDAQ:LQDA) is anticipated to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $116.6210 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million for the quarter, compared to analysts’ expectations of $87.49 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company’s quarterly revenue was up 3072.4% on a year-over-year basis. On average, analysts expect Liquidia to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Liquidia Price Performance

NASDAQ:LQDA traded up $1.26 during trading hours on Tuesday, reaching $39.74. 619,268 shares of the company traded hands, compared to its average volume of 1,631,965. The firm’s 50-day moving average is $36.47 and its 200-day moving average is $34.32. The stock has a market cap of $3.53 billion, a P/E ratio of -47.87 and a beta of 0.41. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. Liquidia has a 1-year low of $11.85 and a 1-year high of $46.67.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on LQDA shares. Needham & Company LLC increased their target price on Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a report on Thursday, March 5th. BTIG Research increased their target price on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Finally, Zacks Research lowered Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.44.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 32,744 shares of the stock in a transaction on Monday, April 13th. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28. Following the completion of the sale, the chief executive officer directly owned 1,137,599 shares in the company, valued at approximately $43,649,673.63. This represents a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 62,550 shares of the stock in a transaction on Friday, March 27th. The shares were sold at an average price of $35.94, for a total value of $2,248,047.00. Following the completion of the sale, the director owned 2,188,935 shares of the company’s stock, valued at approximately $78,670,323.90. This represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 578,820 shares of company stock valued at $22,746,258. 26.50% of the stock is currently owned by company insiders.

Institutional Trading of Liquidia

Several large investors have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC acquired a new stake in shares of Liquidia during the third quarter valued at about $38,887,000. MPM Bioimpact LLC grew its stake in shares of Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Liquidia during the third quarter valued at about $12,571,000. Invesco Ltd. grew its stake in shares of Liquidia by 428.3% during the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after acquiring an additional 341,009 shares in the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Liquidia during the fourth quarter valued at about $10,587,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).